| Entry |
|
|---|
| Name |
Anakinra (USAN/INN);
Anakinra (genetical recombination) (JAN);
Kineret (TN) |
|---|
| Product |
|
|---|
| Formula |
C759H1186N208O232S10
|
|---|
| Exact mass |
17246.4608
|
|---|
| Mol weight |
17257.47
|
|---|
| Sequence |
MRPSGRKSSK MQAFRIWDVN QKTFYLRNNQ LVAGYLQGPN VNLEEKIDVV PIEPHALFLG
IHGGKMCLSC VKSGDETRLQ LEAVNITDLS ENRKQDKRFA FIRSDSGPTT SFESAACPGW
FLCTAMEADQ PVSLTNMPDE GVMVTKFYFQ EDE |
|---|
| Type |
Peptide |
|---|
| Class |
Immunological agent
DG02019 Interleukin inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Anti-inflammatory, Immunosuppressant |
|---|
| Disease |
Active rheumatoid arthritis [DS: H00630] Cryopyrin-associated periodic syndromes [DS: H00282] Deficiency of interleukin-1 receptor antagonist [DS: H01275] |
|---|
| Comment |
recombinant form of human IL-1 receptor antagonist (rhuIL-1Ra) [HSA: 3557] [KO: K05481]
Treatment of inflammatory bowel disease
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04750 | Inflammatory mediator regulation of TRP channels |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AC Interleukin inhibitors
L04AC03 Anakinra
D02934 Anakinra (USAN/INN) <US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Interleukin Blockers
Anakinra
D02934 Anakinra (USAN/INN)
Drug groups [BR:br08330]
Immunological agent
DG02019 Interleukin inhibitor
D02934 Anakinra
Drug classes [BR:br08332]
Immunological agent
DG02019 Interleukin inhibitor
D02934 Anakinra
Target-based classification of drugs [BR:br08310]
Signaling molecules and receptors
Cytokine receptors
Interleukin receptors
IL1R (CD121)
D02934 Anakinra (USAN/INN) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02934
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
